ACAD vs BHVN
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for CNS disorders and rare diseases. BHVN: Biohaven is a clinical-stage biopharmaceutical company developing innovative therapies for immunology, neurological disorders, and metabolic diseases using proprietary protein degradation and ion channel platforms.
Side-by-side fundamentals
| Metric | ACAD | BHVN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.96 | $14.75 | |
| Market cap as of 2026-07-23 | $4.4B | $2.3B | |
| P/E as of 2026-07-23 | 11.59 | n/a | |
| PEG as of 2026-07-23 | -5.27 | n/a | |
| Net margin as of 2026-07-23 | +34.3% | n/a | |
| Gross margin as of 2026-07-23 | +91.5% | n/a | |
| Operating margin as of 2026-07-23 | +7.4% | n/a | |
| ROE as of 2026-07-23 | +35.6% | -450.0% | ACAD higher |
| ROA as of 2026-07-23 | +26.2% | -138.0% | ACAD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.87 | ACAD lower |
| Revenue growth (YoY) as of 2026-07-23 | -13.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +27.5% | n/a | |
| Beta as of 2026-07-23 | 0.86 | 2.98 | |
| 1-year return as of 2026-07-22 close | +10.6% | +12.3% | BHVN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.